Skip to main content

By Ben Hirschler

Drugmaker GlaxoSmithKline, which was slapped with a record $489 million fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates.

Britain's biggest pharmaceuticals group confirmed the investigation following allegations of improper payments set out in a whistleblower's email sent to its top management on Monday. The email, purporting to be from a GSK sales manager in the Gulf state, was seen by Reuters.

The company is already investigating alleged bribery in a number of Middle East countries, including Lebanon, Jordan, Syria and Iraq, as well as Poland.

"As we have already said, we are undertaking an investigation into our operations in the Middle East following complaints made previously. This investigation continues and these specific claims were already being investigated as part of this process," a GSK spokesman said.

GSK and other major drugmakers are under increased scrutiny in the wake of the high-profile Chinese case and law enforcement agencies in both the United States and Britain are clamping down on overseas corruption by multinational companies.

The China scandal has hit GSK's drug sales in the country and tarnished the reputation of Chief Executive Andrew Witty.

Other pharmaceutical companies, too, are in the firing line for alleged improper sales behavior.

France's Sanofi said on Monday it had informed U.S. authorities of allegations of improper payments by its employees to healthcare professionals in East Africa and the Middle East.

Novartis, meanwhile, has been ordered to face a U.S. government lawsuit accusing the Swiss drugmaker of paying multimillion-dollar kickbacks.

And two women in Poland have pleaded guilty to bribery in another case involving an unnamed company.

In the case involving GSK's practices in the UAE, the anonymous author of the email claimed that the British company made direct payments to healthcare professionals, hospitals, clinics and pharmacies to secure business.

This included payments for educational meetings -- regardless of whether or not they took place -- as well as schemes to pay customers for taking prescription drugs by giving them bonus over-the-counter products, the author said.

"We have zero tolerance for unethical behavior and we welcome people speaking up if they have concerns about alleged misconduct. We are committed to taking any disciplinary actions resulting from the findings," the GSK spokesman said.

 

Related Articles

HKIAC 2024年数据出炉,各项核心业务指标均创历史新高(ZH/EN)

by Charlie Wu 吴卓言 |

近日,香港国际仲裁中心(HKIAC)2024年案件统计数据发布,结果显示,其各项核心业务指标在过去一年均创历史新高,进一步巩固了香港作为国际争议解决中心的领先地位。

2025 ALB China 十五佳首席合规官 / Ranking open: 2025 ALB China Top 15 Chief Compliance Officers

ALB荣幸地宣布,2025 ALB China 十五佳首席合规官评选现已启动,此次评选面向工作城市位于中国大陆的的首席合规官或企业合规事务的最高负责者进行参与。

佳利成为最新一家调整中国业务的“白鞋所”(ZH/EN)

2月17日晚,美国佳利律师事务所宣布,其将于今年7月起将北京业务与香港业务合并,关闭北京办公室,并将大中华区业务整合至香港。